Health & Biotech Biotech New Prescient leadership to drive PTX-100 development in rare blood cancer
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Prescient is focused on developing new therapies for cancers with unmet needs.
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range...
It’s a wrap for the September quarter. Here are some of the latest highlights from...
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in...
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.